Siltuximab it is used for cancer treatment using anti-ICOS antibody if patient has low peripheral T cell receptor clonality.
Chimeric (human-murine) immunoglobulin G1κ
(IgG1κ) monoclonal antibody:
Treatment of multicentric Castleman’s disease
(MCD)
Potentially hazardous interactions with other drugs
Live vaccines: risk of generalised infections - avoid.
Ciclosporin and tacrolimus: monitor levels on
initiation and discontinuation of siltuximab as it may
reduce the activity of CYP450.
As siltuximab is a monoclonal antibody, the expected
consequence of metabolism is proteolytic degradation to
small peptides and individual amino acids, and receptormediated clearance.
